On this episode of Stock Movers:
- Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as 2027.
- La-Z Boy (LZB) shares tumble after the furniture maker’s forecast sales for the second quarter missed the average analyst estimate. KeyBanc Capital Markets analyst Bradley Thomas says the company “issued F2Q sales and implied EPS guidance below consensus, pressured in part by continued investments”
- Norfolk Southern Corp (NSC) climbs after a federal regulator resumed its review of Union Pacific’s bid for the rival. The Surface Transportation Board established a procedural schedule for public comment, with participants having until Sept. 4 to file a notice of intent to participate in the review process.

On this episode of Stock Movers: - Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck &amp; Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck&rsquo;s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer St&eacute;phane Bancel saying the product could be approved as soon as 2027. - La-Z Boy (LZB) shares tumble after the furniture maker&rsquo;s forecast sales for the second quarter missed the average analyst estimate. KeyBanc Capital Markets analyst Bradley Thomas says the company &ldquo;issued F2Q sales and implied EPS guidance below consensus, pressured in part by continued investments&rdquo; - Norfolk Southern Corp (NSC) climbs after a federal regulator resumed its review of Union Pacific&rsquo;s bid for the rival. The Surface Transportation Board established a procedural schedule for public comment, with participants having until Sept. 4 to file a notice of intent to participate in the review process.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. 

Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for five-minute conversations on today's biggest winners and losers in the stock market.&nbsp;
Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Moderna Rises, La-Z Boy Drops, Norfolk Southern Corp Climbs as Regulator Resumes Review of Bid From Rival

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d41056e6-dc59-4f1d-8902-b4ab00eb372a/transcript

On this episode of Stock Movers:


-SK Hynix ADRs rose. SK Hynix Inc. unveiled plans to buy back 40 trillion won ($29 billion) of shares and return more profits to investors, moving to stabilize its shares after they fell more than 50% in two months. The memory chipmaker said it will buy back as many as 24 million shares between Aug. 20 and Nov. 19 and cancel them, according to a regulatory filing Wednesday. It also raised its shareholder return pledge to more than 50% of cumulative free cash flow from 2025 to 2027, equivalent to about $170 billion, according to Bloomberg calculations.

 
-Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer Stéphane Bancel saying the product could be approved as soon as 2027.


-Estee Lauder (EL) shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and organic sales growth accelerated to 5%. The company reaffirmed guidance for organic net sales growth of 3% to 5% in its current fiscal year, and raised guidance on its adjusted operating margin.

On this episode of Stock Movers:
 -SK Hynix ADRs rose. SK Hynix Inc. unveiled plans to buy back 40 trillion won ($29 billion) of shares and return more profits to investors, moving to stabilize its shares after they fell more than 50% in two months. The memory chipmaker said it will buy back as many as 24 million shares between Aug. 20 and Nov. 19 and cancel them, according to a regulatory filing Wednesday. It also raised its shareholder return pledge to more than 50% of cumulative free cash flow from 2025 to 2027, equivalent to about $170 billion, according to Bloomberg calculations.
&nbsp; -Moderna (MRNA) shares rise. A personalized vaccine developed by Moderna Inc. and Merck &amp; Co. helped reduce the recurrence of melanoma in a large, late-stage trial. The trial met its main goal of showing that the vaccine, combined with Merck&rsquo;s immune drug Keytruda, reduced melanoma recurrences more than the immunotherapy alone. The companies will discuss filing for approval with regulators and will present the data at an upcoming medical meeting, with Moderna Chief Executive Officer St&eacute;phane Bancel saying the product could be approved as soon as 2027.
 -Estee Lauder (EL) shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and organic sales growth accelerated to 5%. The company reaffirmed guidance for organic net sales growth of 3% to 5% in its current fiscal year, and raised guidance on its adjusted operating margin.

SK Hynix Rises, Moderna Gains, Estee Lauder Soars as Results Show Turnaround Gaining Steam 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/78785750-0b63-42b0-b1e5-b4ab010313e5/transcript

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- Shares of Moderna (MRNA) surged by a record 101% - the stock’s biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.’s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday.

- Shares of Estee Lauder (EL) rallied after the beauty company’s adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views.

- Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker’s forecast sales for the second quarter missed the average analyst estimate.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Shares of Moderna (MRNA) surged by a record 101% - the stock&rsquo;s biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck &amp; Co.&rsquo;s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday.
- Shares of Estee Lauder (EL) rallied after the beauty company&rsquo;s adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views.
- Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker&rsquo;s forecast sales for the second quarter missed the average analyst estimate.

Moderna's Record Surge, Estee Lauder Rises on Q4 Beat, La-Z-Boy Sinks

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/33e42d37-b674-4543-b845-b4ab00e5bc60/transcript

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Shares of Target Corp. (TGT) dipped in the early session. That's despite the retail giant reported comparable sales for the second quarter that beat the average analyst estimate. The company also lifted its full-year guidance after results outpaced estimates in the latest quarter, suggesting the big-box retailer is moving past a lengthy sales slump. The company now expects net sales to increase about 5% in the current fiscal year, which ends in early 2027 — a percentage point higher than the previous guidance.
- Shares of Lowe's Cos. (LOW) slipped in premarket trading after the company cut its outlook for the full year after posting results that missed Wall Street estimates, showing how a stubbornly weak housing market is eroding the home-improvement retailer’s performance. The company now expects comparable sales to be flat this fiscal year, after previously forecasting as much as 2% growth. Comparable sales, which measure results at locations open at least a year, grew 0.2% in the second quarter, missing the average of estimates compiled by Bloomberg.
- Shares of Moderna (MRNA) surged as much as 80% in premarket trading  after the company joined Merck (MRK) to announce their personalized cancer vaccine helped cut the recurrence of melanoma in a large, late-stage trial - an important milestone for the mRNA-based therapy. The trial met its main goal of showing that the vaccine, combined with Merck’s immune drug Keytruda, could lower the rate of melanoma recurrence, compared with the immunotherapy alone. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday.

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Shares of Target Corp. (TGT) dipped in the early session. That's despite the retail giant reported comparable sales for the second quarter that beat the average analyst estimate. The company also lifted its full-year guidance after results outpaced estimates in the latest quarter, suggesting the big-box retailer is moving past a lengthy sales slump. The company now expects net sales to increase about 5% in the current fiscal year, which ends in early 2027 &mdash; a percentage point higher than the previous guidance. - Shares of Lowe's Cos. (LOW) slipped in premarket trading after the company cut its outlook for the full year after posting results that missed Wall Street estimates, showing how a stubbornly weak housing market is eroding the home-improvement retailer&rsquo;s performance. The company now expects comparable sales to be flat this fiscal year, after previously forecasting as much as 2% growth. Comparable sales, which measure results at locations open at least a year, grew 0.2% in the second quarter, missing the average of estimates compiled by Bloomberg. - Shares of Moderna (MRNA) surged as much as 80% in premarket trading&nbsp; after the company joined Merck (MRK) to announce their personalized cancer vaccine helped cut the recurrence of melanoma in a large, late-stage trial - an important milestone for the mRNA-based therapy. The trial met its main goal of showing that the vaccine, combined with Merck&rsquo;s immune drug Keytruda, could lower the rate of melanoma recurrence, compared with the immunotherapy alone. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday.

Target Posts Comp Sales Beat, Lowe's Slips on Outlook, Moderna Soars on Melanoma Study

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/82bb53c0-caff-489f-aa3c-b4ab00b590d6/transcript

Moderna Rises, La-Z Boy Drops, Norfolk Southern Corp Climbs as Regulator Resumes Review of Bid From Rival

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips